ABSTRACT A double blind, randomised, placebo controlled, crossover trial of prednisolone (40 mg/day for 14 days) was carried out in 33 patients with chronic airflow limitation (mean age 62 years, mean FEV1 101 litres, mean FEV1/FVC ratio 44%), to assess the value of serial peak expiratory flow (PEF) measurements, taken five times daily in evaluating treatment response by comparison with other objective measurements and with measurements of symptoms. The mean serial PEF after a one week run in period was 189 1 min-, during the second week of placebo 193 1 min-1, and during the second week on prednisolone 231 1 min-1. The difference in mean PEF values between placebo and prednisolone was significant (p < 0 01). With regard to the response to steroids of the individual patients, 13 of the 33 had a detectable trend of improvement on visual inspection of serial PEF measurements during prednisolone treatment but only one during placebo administration. Of all the objective measurements made after the run in and after each treatment phase (12 minute walking distance, FEV1, forced vital capacity (FVC), serial PEF), the serial PEF chart provided the best discrimination between placebo and prednisolone treatment. There was no statistically significant association between steroid induced improvement in serial PEF measurements and in breathlessness, partly because of placebo improvements in symptoms in those who had no improvement in serial PEF values. This study indicates the importance of making objective measurements to identify a genuine steroid response rather than relying on symptomatic improvement alone. The best simple measurement to make is serial PEF during steroid trials. This is more sensitive in detecting a steroid response than are the 12 minute walking distance, FEV1, or FVC, and is also less likely than these measurements to show spurious placebo responses.
Serial peak expiratory flow (PEF) measurements are of established value in the study of patterns in asthma and of responses to treatment'13 It is usual to measure PEF serially in patients with chronic airflow limitation both during the treatment of acute exacerbations of disease in hospital and in the assessment of response to bronchodilators or corticosteroids in patients with stable disease. The value of this practice has not been established, although an improvement in the serial PEF measurements is generally assumed to be correlated with clinical improvement. The amplitude of changes in serial PEF after treatment with bronchodilators or corticosteroids is usually much smaller in patients with chronic airflow limitation than in asthmatic patients, and may also be less than the natural diurnal variation seen in these patients over a period of time. 4 The present study was done to assess the value of serial PEF measurements in patients with chronic airflow limitation during a double blind crossover controlled trial of oral corticosteroids when compared with changes in symptoms and with other commonly used objective measurements of response.
Methods
We studied 33 (26 male) patients aged (mean 61-7) years with moderate to severe chronic airflow limitation (mean FEV1/forced vital capacity (FVC)) ratio 44%, 58% predicted. The mean FEV1 was 1-011 (36% -predicted;-range 0-44-1-77%) and the mean FVC was 2-291(63% predicted). All patients had had
Value of serial PEF measurements in assessing treatment response in chronic airflow limitation progressive breathlessness on exertion for at least five years, and all had been closely followed at a chest clinic for at least two years. None of the patients was known to have asthma in that there was no history of episodic wheeze, cough, or breathlessness. FEV1 measurements had not varied by more than 20% at clinic visits in any patient, nor had any of the patients had a 20% or greater improvement in peak expiratory flow (PEF), FEV1, or FVC after inhalation of 400 jig salbutamol by aerosol. One patient had sputum eosinophilia. All patients were clinically stable before and during the study in that there had been no recent variation in breathlessness and no infective exacerbation. None had previously received oral corticosteroids and none was taking inhaled steroids. All had smoked (mean 26-2 cigarettes a day for 34-7 years) but most had stopped some time before the study. Most 2, 6 , and 10 pm were recorded on a serial PEF chart for each patient during the run in and both treatment phases. All PEF measurements were made before routine aerosol bronchodilators had been given.
PEF measurements were supervised and recorded by a nurse trained in the correct use of the meter. After the run in period and after each phase of treatment the following measurements were made. Breathlessness was assessed in terms of a simple breathlessness score (1-5)s and oxygen cost diagram.' Each patient completed a 10 cm visual analogue line self assessment rating for feelings of general well being.
After each treatment patients were asked whether they felt better, worse, or unchanged. Exercise performance was measured on the basis of the 12 minute walking distance.6 Each patient did a practice walk several hours before the baseline 12 minute walk was performed. All measurements were made at the same time of day for each patient before routine bronchodilators had been taken. An improvement in a measurement after treatment was arbitrarily taken as a 20% or greater increase when compared with the baseline value. Any visually detectable positive gradient in the serial PEF chart after the run in period or either treatment phase was scored as an improvement. This was assessed before the randomisation code was broken. The overall mean PEF for each patient and the mean PEF at 6 am were calculated for the baseline period of one week, for the second week of the placebo period, and for the second week of the prednisolone period. The following indices of variability in PEF readings during each period were also calculated. The difference between the minimum and maximum PEF readings during the weekly period was expressed as a percentage of the mean PEF for the week. The mean diurnal variation was calculated from the minimum and maximum of each day's PEF values during each weekly period and expressed as a percentage of the mean PEF for the week. Results were analysed by x2 test with Yates's correction. The mean PEF values calculated from the serial charts were compared using Wilcoxon's signed pairs rank sum test.
Results
The numbers of patients showing an improvement (> 20% increase) in each measurement after prednisolone only, after placebo only, and after both prednisolone and placebo are shown in table 1. Visual inspection of the serial PEF charts of the 33 patients for the five week study period showed that improvement occurred solely during the prednisolone phase in 13. No improvements were seen during any phase (run in, placebo, or prednisolone period) in 15 patients; in four patients serial PEF measurements improved during both placebo and prednisolone periods and in the final patient improvement was seen during the run in and placebo periods but not during prednisolone treatment. Nearly as many patients showed improvements in terms of breathlesssness and exercise tolerance (12 minute walk) after placebo as after prednisolone, but there were fewer placebo responses seen in FEV1, FVC, and the serial PEF chart. The placebo responses were not due to a carry over effect of prednisolone into the placebo period, for when data on patients receiving placebo after prednisolone were analysed separately from data on those receiving placebo first there was no excess of placebo improvements for any measurement in the first group.
A comparison between improvements in serial PEF charts and improvements in the other measurements is made in table 2. There were no statistically significant associations between improvements on the PEF chart and any other measurement (X2 tests with tThere was no significant association between improvements on the PEF chart and improvement in any other measurement (X2 with
Yates's correction). (table 1) . This may simply be related to the large number of measurements of PEF made, which increased the signal to noise ratio; whereas symptoms, exercise tolerance, FEV1, and FVC were measured only at the end of the run in and of each treatment phase. The better discrimination of the PEF chart is less likely to have been due to a positive trend that was evident with very small percentage increases in mean values between baseline and prednisolone, while other measurements were scored as an improvement only if there had been a 20% or greater increment. Of the 13 patients with a positive trend on the peak flow chart, all but two had a mean PEF value in the second week of prednisolone that was 20% or more above the baseline mean.
Steroid induced improvements in serial PEF measurements were not necessarily accompanied by improvements in symptoms, exercise tolerance, FEV1, or FVC, and such associations as there were did not reach statistical significance, perhaps because numbers were small. It was, however, noteworthy that only one or two subjects without improved PEF measurements after taking steroids showed improvements in other objective measurements, whereas larger numbers had improved symptoms in the face of no improvement in PEF measurements. This, taken together with the observation that the PEF chart was the best discriminator between placebo and prednisolone, would indicate that the PEF chart was the most 
